Ellsworth Advisors’s Immunovant IMVT Stock Holding History

Ellsworth Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,280	Closed	-$802K	–	193
2026 Q1	$802K	Buy	+32,280	New	+$836K	0.15%	123

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ellsworth Advisors's IMVT Position: Q2 2026 in Review

Ellsworth Advisors sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 32,280 shares — an estimated $802K sold.

Ellsworth Advisors first reported a position in IMVT in Q1 2026 and held it in 1 quarter. The position peaked at $802K in Q1 2026. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Ellsworth Advisors reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
Ellsworth Advisors sold 32,280 Immunovant shares in Q2 2026, an estimated $802K.
Ellsworth Advisors first reported a position in Immunovant in Q1 2026 and held it in 1 quarter.
Ellsworth Advisors's Immunovant position peaked at $802K in Q1 2026.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.